Synergistic methodologies for the synthesis of 3-aroyl-2- arylbenzo[b]thiophene-based selective estrogen receptor modulators. Two concise syntheses of raloxifene

Tetrahedron Letters

Volumn 40, Issue 28, 1999, Pages 5155-5159

  Bradley, David A ^a   Godfrey, Alexander G ^a   Schmid, Christopher R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE;

ACYLATION; ARTICLE; CHEMICAL REACTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

EID: 0033538646     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(99)00955-7     Document Type: Article

References (35)

1. (a) Grese, T. A.; Dodge, J. A. Curr. Pharm. Des. 1998, 4, 71-92.
2. (b) Bryant, H. U; Dere, W. H. Proc. Soc. Exp. Biol. Med. 1998, 217, 45-52.
3. Marketed as Evista® (Raloxifene Hydrochloride 60 mg).
4. (a) Jones, C. D.; Jevikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. J. Med. Chem. 1984, 27, 1057-1066.
5. (b) Sato, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. J. Med. Chem. 1999, 42, 1-24.
6. (c) Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. J. Bone Mineral Res. 1996, 11, 835-842.
7. (a) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Proc. Nat. Acad. Sci. U.S.A. 1997, 94, 14105-14110.
8. (b) Grese, T, A.; Dodge, J. A. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1996; Vol. 31, pp. 181-190 .
9. (c) Kauffman, R. F.; Bryant, H. U. Drug News Perspect. 1995, 8, 531-539.
10. (d) Evans, G. I; Turner, R. T. Bone 1995, 17, 1818-1908.
11. (a) Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1998, 41, 1272-1283.
12. (b) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. J. Med. Chem. 1997, 40, 1407-1416.
13. (c) Grese, T. A.; Cho, S.; Finley, D. A.; Godfrey, A. G.; Jones, C. D.; Lugar III, C. W.; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1997, 40, 146-167.
14. (d) Martin, M. J.; Grese, T. A.; Glasebrook, A. L.; Matsumoto, K.; Pennington, L. D.; Phillips, D. L.; Short, L. L. Bioorg. Med. Chem. Lett. 1997, 7, 887-892.
15. (e) Cameron, K. O.; Da Silva-Jardine, P.; Larson, E. R.; Hauske, J. R.; Rosati, R. L. PCT Int'l Appl. WO9510513.
16. Sall, D. J.; Bastian, J. A.; Briggs, S. L.; Buben, J. A.; Chirgadze, N. Y; Clawson, D. K.; Denney, M. L.; Giera, D. D.; Gifford-Moore, D. S.; Harper, R. W.; Hauser, K. L.; Klimkowski, V. J.; Kohn, T. J.; Lin, H.-S.; McCowan, J. R.; Palkowitz, A. D.; Smith, G. F.; Takeuchi, K.; Thrasher, K. J.; Tinsley, J. M.; Utterback, B. G.; Yan, S.-C. B.; Zhang, M. J. Med. Chem. 1997, 40, 3489-3493.
17. (a) Godfrey, A. G. U.S. Patent 5 466 810, 1995;
18. Chem. Abstr. 1996, 124, 175, 813.
19. (b) Godfrey, A. G. U.S. Patent 5 420 349, 1995;
20. Chem. Abstr. 1995, 123, 111, 843.
21. (a) Schmid, C. R.; Sluka, J. P.; Duke, K. M. Tetrahedron Lett. 1999, 40, 675-678.
22. (b) Schmid, C. R.; Sluka, J. P.; Duke, K. M.; Glasebrook, A. W. Bioorg. Med. Chem. Lett. 1999, 9, 523-528.
23. Ablenas, F. J.; George, B. E.; Maleki, M.; Jain, R.; Hopkinson, A. C.; Lee-Ruff, E. Can. J. Chem. 1987, 65, 1800-1803. All compounds exhibited satisfactory spectral (IR, PMR, CMR) and analytical (EA or HRMS) data.
24. (a) Shirley, D. A.; Cameron, M. D. J. Am. Chem. Soc. 1952, 74, 664-665.
25. (b) Fries, K.; Hemmecke, B. Ann. 1929, 470, 1.
26. Wolfe, J. P.; Wagaw, S.; Buchwald, S. L. J. Am. Chem. Soc. 1996, 118, 7215-7216.
27. (a) March, J. Advanced Organic Chemistry, 3rd Ed.; Wiley-Interscience: New York, 1985; p. 585.
28. (b) Bernasconi, C. F. Chimia 1980, 34, 1-11.
29. NAr has been used on a highly activated perfluorobenzoyl group to prepare a benzothiophene-based reagent for photoaffinity labeling of the estrogen receptor. See
30. NAr conditions employing dipolar aprotic solvents on substrates of similar reactivity have recently appeared. See
31. (e) Berge, J.; Moore, G. N. Synlett 1994, 187-188.
32. (f) Ziegler, C. B.; Curran, W. V.; Kuck, N. A.; Harris, S, M.; Lin, Y.-I. J. Heterocyclic Chem. 1989, 26, 1141.
33. Colleagues at Lilly have recently disclosed application of our methodology to the preparation of thrombin inhibitors. See: (a) Sall, D. J.; Briggs, S. L; Chirgadze, N. Y; Clawson, D. K.; Gifford-Moore, D. S,; Klimkowshi, V. J.; McCowan, J. R.; Smith, G. F.; Wikel, J. H. Bioorg. Med. Chem. Lett. 1998, 8, 2527-2532.
34. (b) Bastian, J. A.; Chirgadze, N.; Denney, M. L.; Gifford-Moore, D. S.; Sall, D. J.; Smith, G. F.; Wikel, J. H. Bioorg. Med. Chem. Lett. 1999, 9, 363-368.
35. (c) Takeuchi, K.; Kohn, T. J.; Sall, D. J.; Denney, M. L.; McGowan, J. R.; Smith, G. F.; Gifford-Moore, D. S. Bioorg. Med. Chem. Lett 1999, 9, 759-764.